Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

61.19 +1.16 (+1.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,098,491
Open 61.10
Bid (Size) 60.80 (2)
Ask (Size) 61.69 (1)
Prev. Close 60.03
Today's Range 60.63 - 62.08
52wk Range 40.19 - 66.00
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
While growth is established for HALOZYME THERAPEUTICS INC (NASDAQ:HALO), the stock's valuation remains reasonable.
HALOZYME THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:HALO is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably. 
Via Chartmill
Deep Dive Into Halozyme Therapeutics Stock: Analyst Perspectives (5 Ratings)
Via Benzinga

Performance

YTD
+27.5%
+27.5%
1 Month
+2.6%
+2.6%
3 Month
+8.7%
+8.7%
6 Month
+4.7%
+4.7%
1 Year
+49.8%
+49.8%

More News

Read More
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief
Via Stocktwits
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
Via Benzinga
HALOZYME THERAPEUTICS INC (NASDAQ:HALO), a strong growth stock, setting up for a breakout.
Via Chartmill
Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts
Via Benzinga
Demystifying Halozyme Therapeutics: Insights From 8 Analyst Reviews
Via Benzinga
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
Via Benzinga
Exposures Product Safety
Peering Into Halozyme Therapeutics's Recent Short Interest
Via Benzinga
Investors should take notice of HALOZYME THERAPEUTICS INC (NASDAQ:HALO)—it offers a great deal for the fundamentals it presents.
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing good growth, while it is not too expensive.
Via Chartmill
Is HALOZYME THERAPEUTICS INC (NASDAQ:HALO) a Minervini-style stock?
Via Chartmill
Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
Looking for growth without the hefty price tag? Consider HALOZYME THERAPEUTICS INC (NASDAQ:HALO).
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Technical Analysis observations.
Via Chartmill
NASDAQ:HALO: a strong growth stock preparing for the next leg up?.
Via Chartmill
Earnings Scheduled For February 18, 2025
Via Benzinga
NASDAQ:HALO is not too expensive for the growth it is showing.
Via Chartmill
NASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why.
Via Chartmill
NASDAQ:HALO—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via Chartmill
In the world of growth stocks, NASDAQ:HALO shines as a value proposition.
Via Chartmill
In a market where value is scarce, NASDAQ:HALO offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
BeiGene Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily

Frequently Asked Questions

Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
The current price of Halozyme Therapeutics, Inc. - Common Stock is 61.19
When was Halozyme Therapeutics, Inc. - Common Stock last traded?
The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 05/02/25 04:00 PM ET
What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 8.71B
How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
Halozyme Therapeutics, Inc. - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.